Amgen Gets Approval for Repatha

The Federal Drug Administration has authorized Amgen Inc. to sell its drug Repatha to some patients with very high cholesterol. It could add up to big money for the Thousand Oaks company, the Los Angeles Times reports, but insurance companies may balk at the price, which starts at $14,100 for a year’s worth of treatment.